ELECTRA THERAPEUTICS INC
- Market cap
- 559.68M
- P/E (TTM)i
- -5.88
- P/Bi
- -2.55
- EPSi
- -1.01
- Div yieldi
- 0.00%
- 52W posi
- 4%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 7 in the most recent period (2026/Q3).
- Total institutional ownership rose 51.0 percentage points.
Institutional ownership
- Held by institutions
- 50.98% +50.98pp
- Institutions
- 7 +7
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 14 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-09-25
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
21 filings tracked · 6 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| OrbiMed Advisors LLC | -- | 10.97% |
| Westlake Village BioPartners | -- | 10.11% |
| Quehuong Dong | Chief Executive Officer | 0.73% |
| Nancy Stagliano | Independent Chairperson | 0.41% |
| Graham Parry | Chief Scientific Officer | 0.14% |
| Gary Koe | Chief Technology Officer | 0.10% |
| Carl Gordon | Independent Director | -- |
| Matthew Fust | Independent Director | -- |
| David Tucker | Former Officer | -- |
| Kim-Hien Dao | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-20 | OrbiMed Advisors LLC | -- | Private Acquisition | +1,333,333 | $15.00 |
| 2026-09-20 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +5,551,837 | -- |
| 2026-09-20 | Nancy Stagliano | Independent Chairperson | Derivative Exercise and Retained | +255,635 | -- |
| 2026-09-20 | Graham Parry | Chief Scientific Officer | Derivative Exercise and Retained | +85,504 | -- |
| 2026-09-20 | Quehuong Dong | Chief Executive Officer | Derivative Exercise and Retained | +455,484 | -- |
| 2026-09-20 | Westlake Village BioPartners | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-09-20 | Gary Koe | Chief Technology Officer | Derivative Exercise and Retained | +63,656 | -- |
| 2026-09-17 | Carl Gordon | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Matthew Fust | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | David Tucker | Former Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Nancy Stagliano | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Graham Parry | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Quehuong Dong | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Kim-Hien Dao | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Gary Koe | Chief Technology Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:46:40 · For reference only, not investment advice and not tailored to your situation.